[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,103,948
  • Shares Outstanding, K 79,793
  • Annual Sales, $ 517,150 K
  • Annual Income, $ 66,350 K
  • EBIT $ 80 M
  • EBITDA $ 98 M
  • 60-Month Beta 1.89
  • Price/Sales 5.90
  • Price/Cash Flow 25.68
  • Price/Book 2.27

Options Overview Details

View History
  • Implied Volatility 59.12% (-2.47%)
  • Historical Volatility 73.92%
  • IV Percentile 28%
  • IV Rank 28.54%
  • IV High 101.25% on 05/04/26
  • IV Low 42.30% on 08/13/25
  • Expected Move (DTE 34) 6.38 (16.58%)
  • Put/Call Vol Ratio 7.00
  • Today's Volume 24
  • Volume Avg (30-Day) 138
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 3,658
  • Open Int (30-Day) 2,432
  • Expected Range 32.08 to 44.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.30
  • Number of Estimates 3
  • High Estimate $0.31
  • Low Estimate $0.30
  • Prior Year $0.31
  • Growth Rate Est. (year over year) -3.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.16 +23.80%
on 04/29/26
42.10 -8.37%
on 05/07/26
+4.53 (+13.32%)
since 04/15/26
3-Month
29.45 +30.96%
on 03/27/26
42.10 -8.37%
on 05/07/26
+2.81 (+7.84%)
since 02/13/26
52-Week
22.61 +70.61%
on 07/18/25
50.71 -23.93%
on 11/25/25
+10.09 (+35.40%)
since 05/15/25

Most Recent Stories

More News
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer

Marks the first Medicare coverage decision for Veracyte’s whole-genome sequencing-based TrueMRD platform and launch of the first test

VCYT : 39.04 (+0.36%)
Veracyte: Q1 Earnings Snapshot

Veracyte: Q1 Earnings Snapshot

VCYT : 39.04 (+0.36%)
Veracyte Announces First Quarter 2026 Financial Results

Grew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively Conference...

VCYT : 39.04 (+0.36%)
Veracyte's Conference Call: Where Oncology Diagnostics Meet the Art of Expectations Management

Barchart Research What to Expect from VCYT Earnings VCYT Generated May 4, 2026 Current Price $33.45 EPS Estimate $$0.23 Consensus Rating Moderate Buy Average Move 12.24% Veracyte's Conference Call: Where...

VCYT : 39.04 (+0.36%)
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using real-world data

VCYT : 39.04 (+0.36%)
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May...

VCYT : 39.04 (+0.36%)
Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership...

VCYT : 39.04 (+0.36%)
Veracyte: Q4 Earnings Snapshot

Veracyte: Q4 Earnings Snapshot

VCYT : 39.04 (+0.36%)
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Grew fourth quarter total revenue to $140.6 million, an increase of 19% Grew fourth quarter testing revenue to $135.8 million, an increase of 21% ...

VCYT : 39.04 (+0.36%)
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests

VCYT : 39.04 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

3rd Resistance Point 41.30
2nd Resistance Point 40.48
1st Resistance Point 39.69
Last Price 39.04
1st Support Level 38.08
2nd Support Level 37.26
3rd Support Level 36.47

See More

52-Week High 50.71
Fibonacci 61.8% 39.98
Last Price 39.04
Fibonacci 50% 36.66
Fibonacci 38.2% 33.34
52-Week Low 22.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.